CD47-targeting therapies have extensive preclinical validation, and targeting CD47 with monoclonal antibodies (MAbs) in xenograft models of ovarian, colon, breast, bladder, lung, pancreatic carcinoma, glioma, and leiomyosarcoma enhances macrophage activity and tumor elimination [29,45,46]. The gene discussed is CD47; the disease is exocrine pancreatic carcinoma.